XOMA Corporation (XOMA)
| Previous Close | 25.64 |
| Open | 25.55 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 25.20 - 26.75 |
| 52 Week Range | 13.48 - 27.00 |
| Volume | |
| Avg. Volume | 18,893 |
| Market Cap | 301.571M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.04 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | 2.16 (8.41%) |
| Ex-Dividend Date | Apr 02, 2024 |
| 1y Target Est | N/A |
GlobeNewswireXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
Simply Wall St.XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...
